Anti-α-galactosyl antibody

Anti-α-galactosyl antibodies, also called anti-Gal antibodies, are naturally occurring polyclonal antibodies present in high titers (about 1% of serum IgG) in humans, apes, and Old World monkeys, but not in New World monkeys or most other mammals. They specifically recognize the carbohydrate epitope Galα1–3Galβ1–4GlcNAc (α-Gal), which is not synthesized by humans but is common on the cells of non-primate mammals, many bacteria, and some parasites. These antibodies develop in early life due to immune stimulation from gut flora carrying the α-Gal epitope and are found in several immunoglobulin classes (mainly IgG, but also IgA and IgM)[5][6][7]. Anti-α-galactosyl antibodies play roles in innate immunity, xenotransplantation rejection, and allergic reactions to mammalian meat (α-Gal syndrome), and interact with certain therapeutic monoclonal antibodies (e.g., cetuximab) containing α-Gal epitopes. They achieve their effects via complement activation, Fc receptor-mediated phagocytosis, and antigen presentation pathways[1][2][3][6]. Note: This entry describes an antibody, not a conventional drug target like a receptor or enzyme. Anti-α-galactosyl antibody is not a typical therapeutic target but rather a naturally occurring immune effector. Its clinical significance arises from its role in immune recognition and its implications in transplantation, infectious disease, and allergies. This makes it not a classic targetable receptor or protein but an analyte of immunological interest[1][2][3][6].

Other names

Anti-Gal antibodyanti-alpha-galactosyl antibodyanti-Gal

Binds α-Gal epitopes on non-human cells or molecules, leading to complement activation and opsonization. Can trigger antibody-dependent cellular cytotoxicity and other effector functions via Fc receptor binding.